This site is intended for healthcare professionals
UCB EHSF 2024
Advances in hidradenitis suppurativa
Declaration of sponsorship UCB Biopharma SRL

Transcript: Most important issue

Declaration of sponsorship UCB Biopharma SRL
Last updated:21st Oct 2024
Published:21st Oct 2024

Aikaterini Liakou

Interview recorded Sep 2024, EADV 2024. All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.

So I think that the most important issue addressed in this congress about the hidradenitis, is the new European guidelines. The new European guidelines, which are accepted this year in the European Journal, come 10 years after the last guidelines, which have been published in 2015. So for us, for the physicians it's something very important, and also for patients, of course. In the new European guidelines, there are many differences. There are, for example, there is a new clinical classification of the disease. There are two types of the disease, clinically, like the inflammatory and the non-inflammatory type. There is guidance on how to treat every stage of the disease and every type of the disease. Very, very important. And of course, there are new medications. There are new treatments which are listed in the guidelines. There are new treatments registered for the disease, which is a revolution for the physicians and for the patients.

View the video

Welcome: